ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biologics

Lonza to supply Remsima

by Alex Scott
September 6, 2019 | APPEARED IN VOLUME 97, ISSUE 35

 

Lonza has agreed to manufacture the biologic drug Remsima for Celltrion at its facilities in Singapore to meet growing demand in North America and Europe. Remsima is a biosimilar monoclonal antibody medication approved in Europe and the US for treating a variety of autoimmune diseases. Separately, a joint venture formed earlier this year between Lonza and the Danish foods firm Chr. Hansen to manufacture live therapeutic microbes for the emerging microbiome drug sector has received approval from regulators. Named BacThera, the partnership is upgrading facilities in Horsholm, Denmark, and Basel, Switzerland, to serve preclinical-to-Phase II projects.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment